Free Trial
→ U.S. Government Sparking Crypto Rally (From Crypto 101 Media) (Ad)tc pixel Free AUTL Stock Alerts

Autolus Therapeutics (AUTL) Financials

Autolus Therapeutics logo
$1.53 +0.03 (+2.00%)
Closing price 10/24/2025 04:00 PM Eastern
Extended Trading
$1.54 +0.01 (+0.98%)
As of 10/24/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Autolus Therapeutics

Annual Income Statements for Autolus Therapeutics

This table shows Autolus Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 9/30/2016 9/30/2017 9/30/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -13 -19 -45 -124 -142 -145 -149 -208 -221
Consolidated Net Income / (Loss)		 -13 -20 -45 -124 -142 -142 -149 -208 -221
Net Income / (Loss) Continuing Operations		 -13 -20 -45 -124 -142 -142 -149 -208 -221
Total Pre-Tax Income 		-14 -23 -52 -139 -166 -142 -149 -208 -219
Total Operating Income		 -14 -23 -58 -146 -168 -141 -143 -180 -241
Total Gross Profit		 1.21 1.69 1.41 2.91 1.72 2.33 6.36 1.70 -1.27
Total Revenue		 1.21 1.69 1.41 2.91 1.72 2.33 6.36 1.70 10
Operating Revenue		 1.21 1.69 1.41 2.91 1.72 2.33 6.36 1.70 10
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 11
Operating Cost of Revenue		 - - - - - - - 0.00 11
Total Operating Expenses		 16 25 59 149 170 143 150 181 240
Selling, General & Admin Expense		 5.15 9.10 23 39 35 32 32 47 101
Research & Development Expense		 10 16 36 105 135 111 117 130 138
Impairment Charge		 - 0.00 0.00 4.10 - - 0.00 0.38 0.41
Other Special Charges / (Income)		 - - - 0.00 0.00 0.68 0.52 3.79 0.22
Total Other Income / (Expense), net		 0.05 0.08 5.50 7.06 1.89 -1.98 -5.16 -29 22
Interest Expense		 - - - 0.00 0.00 1.11 8.91 45 9.29
Interest & Investment Income		 0.08 0.08 1.53 2.54 0.54 0.26 1.71 14 32
Other Income / (Expense), net		 -0.03 -0.01 3.97 4.51 1.35 -1.13 2.04 2.86 -0.77
Income Tax Expense		 -1.78 -3.65 -7.28 -15 -24 0.06 0.27 -0.02 1.53
Basic Earnings per Share		 ($1.26) ($1.43) ($1.42) ($2.88) ($2.76) ($1.97) ($1.57) ($1.20) ($0.86)
Weighted Average Basic Shares Outstanding		 9.93M 13.78M 31.56M 43.07M 51.56M 72.08M 94.99M 173.94M 255.16M
Diluted Earnings per Share		 ($1.26) ($1.43) ($1.42) ($2.88) ($2.76) ($1.97) ($1.57) ($1.20) ($0.86)
Weighted Average Diluted Shares Outstanding		 9.93M 13.78M 31.56M 43.07M 51.56M 72.08M 94.99M 173.94M 255.16M
Weighted Average Basic & Diluted Shares Outstanding		 9.93M 13.78M 31.56M 43.07M 51.56M 90.91M 173.07M 265.93M 266.13M

Quarterly Income Statements for Autolus Therapeutics

This table shows Autolus Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -43 -40 -46 -46 -77 -53 -57 -82 -29
Consolidated Net Income / (Loss)		 -43 -40 -46 -46 -77 -53 -58 -82 -28
Net Income / (Loss) Continuing Operations		 -43 -40 -46 -46 -77 -53 -58 -82 -28
Total Pre-Tax Income 		-49 -40 -46 -46 -77 -53 -58 -82 -26
Total Operating Income		 -43 -39 -44 -43 -53 -39 -59 -68 -76
Total Gross Profit		 2.37 1.29 0.00 0.41 - 10 0.00 0.00 -11
Total Revenue		 2.37 1.29 0.00 0.41 - 10 0.00 0.00 0.03
Operating Revenue		 2.37 1.29 0.00 0.41 - 10 0.00 0.00 0.03
Total Cost of Revenue		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 11
Total Operating Expenses		 46 40 44 43 53 49 59 68 65
Selling, General & Admin Expense		 8.23 9.28 11 11 16 18 22 27 34
Research & Development Expense		 38 27 33 32 38 31 37 40 31
Total Other Income / (Expense), net		 -5.43 -0.68 -1.14 -2.97 -24 -14 1.00 -14 49
Interest Expense		 1.85 4.91 5.02 5.01 30 19 10 11 -31
Interest & Investment Income		 0.17 3.45 3.40 3.65 3.01 6.93 9.66 8.32 7.45
Other Income / (Expense), net		 -3.74 0.78 0.48 -1.60 3.19 -1.61 1.52 -12 11
Income Tax Expense		 -6.15 -0.01 0.04 -0.02 -0.02 -0.01 0.05 0.02 1.46
Basic Earnings per Share		 ($0.47) ($0.23) ($0.26) ($0.26) ($0.45) ($0.24) ($0.22) ($0.31) ($0.09)
Weighted Average Basic Shares Outstanding		 91.24M 173.83M 173.86M 173.98M 173.94M 222.17M 266.03M 266.08M 255.16M
Diluted Earnings per Share		 ($0.47) ($0.23) ($0.26) ($0.26) ($0.45) ($0.24) ($0.22) ($0.31) ($0.09)
Weighted Average Diluted Shares Outstanding		 91.24M 173.83M 173.86M 173.98M 173.94M 222.17M 266.03M 266.08M 255.16M
Weighted Average Basic & Diluted Shares Outstanding		 - - - 173.99M 265.93M 266.04M 266.09M 266.12M 266.13M

Annual Cash Flow Statements for Autolus Therapeutics

This table details how cash moves in and out of Autolus Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 9/30/2016 9/30/2017 9/30/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 18 109 110 -6.13 -57 157 72 -142 -12
Net Cash From Operating Activities		 -9.85 -16 -32 -101 -118 -118 -112 -146 -206
Net Cash From Continuing Operating Activities		 -9.85 -16 -32 -101 -118 -118 -112 -146 -205
Net Income / (Loss) Continuing Operations		 -13 -20 -45 -124 -142 -142 -149 -208 -221
Consolidated Net Income / (Loss)		 -13 -20 -45 -124 -142 -142 -149 -208 -221
Depreciation Expense		 0.48 1.01 1.71 4.61 5.66 8.46 7.42 6.57 7.55
Amortization Expense		 - - - - - - - 0.00 0.16
Non-Cash Adjustments To Reconcile Net Income		 3.46 4.24 6.77 37 19 15 29 57 32
Changes in Operating Assets and Liabilities, net		 -1.23 -1.88 4.73 -19 -0.10 0.34 0.27 -0.69 -24
Net Cash From Investing Activities		 -1.86 -2.88 -9.53 -19 -15 -8.86 -11 -11 -395
Net Cash From Continuing Investing Activities		 -1.86 -2.88 -9.53 -19 -15 -8.86 -11 -11 -395
Purchase of Property, Plant & Equipment		 -1.86 -2.88 -9.12 -18 -15 -8.86 -11 -11 -22
Acquisitions		 0.00 0.00 -0.41 -0.33 - - - 0.00 -13
Purchase of Investments		 - - - - - - - 0.00 -360
Net Cash From Financing Activities		 32 128 157 109 74 284 224 -0.88 590
Net Cash From Continuing Financing Activities		 32 128 157 109 74 284 224 -0.88 590
Repurchase of Common Equity		 - - - -7.10 -5.80 -11 -10 -0.91 -29
Issuance of Common Equity		 32 128 157 116 80 246 164 0.00 550
Other Financing Activities, net		 - - - 0.04 0.46 50 70 0.03 69
Effect of Exchange Rate Changes		 -2.66 0.56 -5.83 5.16 0.68 -0.75 -28 15 -0.26
Cash Income Taxes Paid		 - - - 1.54 -20 0.36 0.47 0.55 2.39

Quarterly Cash Flow Statements for Autolus Therapeutics

This table details how cash moves in and out of Autolus Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Change in Cash & Equivalents		 219 -39 -36 -51 -17 519 -53 -48 -430
Net Cash From Operating Activities		 -15 -42 -38 -40 -25 -41 -51 -77 -38
Net Cash From Continuing Operating Activities		 -15 -42 -38 -40 -25 -41 -51 -77 -37
Net Income / (Loss) Continuing Operations		 -27 -40 -46 -46 -77 -53 -58 -82 -28
Consolidated Net Income / (Loss)		 -27 -40 -46 -46 -77 -53 -58 -82 -28
Depreciation Expense		 1.65 1.90 1.51 1.38 1.78 1.81 1.90 1.94 1.92
Non-Cash Adjustments To Reconcile Net Income		 4.75 9.14 5.31 15 27 24 14 1.58 -8.31
Changes in Operating Assets and Liabilities, net		 5.99 -14 0.58 -11 23 -14 -8.84 1.83 -2.85
Net Cash From Investing Activities		 -0.63 -3.62 -4.39 -1.50 -1.48 -0.53 -0.84 -9.59 -384
Net Cash From Continuing Investing Activities		 -0.63 -3.62 -4.39 -1.50 -1.48 -0.53 -0.84 -9.59 -384
Purchase of Property, Plant & Equipment		 -0.63 -3.62 -4.39 -1.50 -1.48 -0.53 -0.84 -9.59 -11
Net Cash From Financing Activities		 224 -0.69 -0.22 0.00 0.02 561 -2.08 0.19 30
Net Cash From Continuing Financing Activities		 224 -0.69 -0.22 0.00 0.02 561 -2.08 0.19 30
Other Financing Activities, net		 70 0.00 - 0.00 0.02 39 -0.24 0.19 30
Effect of Exchange Rate Changes		 11 7.33 7.23 -9.30 9.77 -1.19 1.42 38 -38
Cash Income Taxes Paid		 - - - -0.27 0.55 - - 0.28 1.13

Annual Balance Sheets for Autolus Therapeutics

This table presents Autolus Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 9/30/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 149 254 304 294 406 490 375 783
Total Current Assets		 142 233 249 197 347 426 275 661
Cash & Equivalents		 137 217 211 153 310 382 240 227
Restricted Cash		 0.00 0.11 0.79 0.79 0.34 0.33 0.77 1.43
Short-Term Investments		 - - - - - - 0.00 361
Inventories, net		 - - - - - - 0.00 4.14
Prepaid Expenses		 5.41 15 38 43 36 43 35 67
Plant, Property, & Equipment, net		 6.18 20 28 38 34 35 35 50
Total Noncurrent Assets		 0.00 1.28 26 59 25 29 65 72
Intangible Assets		 0.00 0.00 0.25 0.16 0.07 - 0.00 12
Noncurrent Deferred & Refundable Income Taxes		 - 0.00 0.41 1.75 1.83 2.08 3.06 3.24
Other Noncurrent Operating Assets		 0.00 1.28 25 57 23 27 62 57
Total Liabilities & Shareholders' Equity		 149 254 304 294 406 490 375 783
Total Liabilities		 6.06 22 49 84 92 192 264 355
Total Current Liabilities		 5.03 21 25 34 29 46 45 61
Accounts Payable		 1.95 2.02 1.08 2.26 0.43 0.53 0.10 1.97
Accrued Expenses		 3.09 19 21 28 24 41 40 52
Current Deferred Revenue		 - - - - - - 0.00 3.50
Other Current Liabilities		 - 0.00 2.51 3.59 4.45 5.04 5.05 3.00
Total Noncurrent Liabilities		 1.03 0.49 24 51 64 145 219 295
Noncurrent Deferred Revenue		 - - - 0.00 47 126 171 245
Other Noncurrent Operating Liabilities		 0.27 0.21 24 51 17 19 48 50
Commitments & Contingencies		 - - - 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 143 233 255 210 313 299 111 427
Total Preferred & Common Equity		 143 233 255 210 313 299 111 427
Total Common Equity		 143 233 255 210 313 299 111 427
Common Stock		 194 361 501 595 843 1,008 1,019 1,556
Retained Earnings		 -48 -113 -237 -379 -521 -670 -879 -1,099
Accumulated Other Comprehensive Income / (Loss)		 -3.85 -15 -8.69 -5.86 -8.57 -39 -29 -29

Quarterly Balance Sheets for Autolus Therapeutics

This table presents Autolus Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024
Total Assets		 406 901 854 827
Total Current Assets		 308 804 759 718
Cash & Equivalents		 256 759 706 657
Restricted Cash		 0.43 1.02 1.02 1.47
Prepaid Expenses		 52 45 52 60
Plant, Property, & Equipment, net		 35 33 33 44
Total Noncurrent Assets		 63 64 62 65
Noncurrent Deferred & Refundable Income Taxes		 2.60 3.30 3.22 3.39
Other Noncurrent Operating Assets		 60 60 59 62
Total Liabilities & Shareholders' Equity		 406 901 854 827
Total Liabilities		 226 319 326 351
Total Current Liabilities		 38 44 41 52
Accounts Payable		 0.66 1.40 1.10 1.42
Accrued Expenses		 31 38 36 47
Other Current Liabilities		 5.49 4.82 4.23 3.57
Total Noncurrent Liabilities		 188 275 285 298
Noncurrent Deferred Revenue		 141 228 239 249
Other Noncurrent Operating Liabilities		 47 47 46 49
Commitments & Contingencies		 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 181 582 528 477
Total Preferred & Common Equity		 181 582 528 477
Total Common Equity		 181 582 528 477
Common Stock		 1,016 1,542 1,545 1,549
Retained Earnings		 -801 -931 -990 -1,072
Accumulated Other Comprehensive Income / (Loss)		 -34 -29 -28 -0.90

Annual Metrics And Ratios for Autolus Therapeutics

This table displays calculated financial ratios and metrics derived from Autolus Therapeutics' official financial filings.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 9/30/2016 9/30/2017 9/30/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - - - - - -
Revenue Growth		 0.00% 39.69% -16.89% 106.68% -41.02% 35.86% 172.96% -73.30% 496.00%
EBITDA Growth		 0.00% -61.00% -131.32% -164.09% -17.67% 17.01% -0.17% -27.12% -37.71%
EBIT Growth		 0.00% -62.66% -128.65% -164.27% -17.83% 14.75% 0.57% -25.09% -36.96%
NOPAT Growth		 0.00% -62.90% -145.68% -153.88% -15.12% 16.11% -1.67% -25.31% -34.35%
Net Income Growth		 0.00% -57.19% -126.85% -176.75% -14.73% 0.00% -4.75% -40.01% -5.89%
EPS Growth		 0.00% -13.49% 0.70% -102.82% 4.17% 28.62% 20.30% 23.57% 28.33%
Operating Cash Flow Growth		 0.00% -66.11% -92.77% -221.79% -16.04% -0.09% 4.71% -29.63% -41.68%
Free Cash Flow Firm Growth		 0.00% 0.00% -117.53% -163.99% 0.03% 65.12% 69.95% -493.33% -67.54%
Invested Capital Growth		 0.00% 0.00% 144.23% 182.39% 28.88% -95.27% -3,280.30% -53.25% -25.81%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.29%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -6.51%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -6.43%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -10.32%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 18.34%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 29.51%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -7.59% -6.78%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 10.71%
Profitability Metrics		 - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% -12.52%
EBITDA Margin		 -1,148.84% -1,324.10% -3,685.43% -4,709.04% -9,395.63% -5,739.27% -2,106.10% -10,027.97% -2,316.99%
Operating Margin		 -1,186.14% -1,383.23% -4,089.05% -5,022.83% -9,804.37% -6,053.65% -2,254.84% -10,583.10% -2,385.63%
EBIT Margin		 -1,188.28% -1,383.70% -3,806.89% -4,867.61% -9,725.54% -6,102.27% -2,222.80% -10,414.61% -2,393.23%
Profit (Net Income) Margin		 -1,035.48% -1,165.21% -3,180.60% -4,258.91% -8,285.36% -6,098.54% -2,340.24% -12,272.26% -2,180.45%
Tax Burden Percent		 87.60% 84.38% 86.01% 89.09% 85.47% 100.04% 100.18% 99.99% 100.70%
Interest Burden Percent		 99.48% 99.80% 97.14% 98.20% 99.68% 99.90% 105.09% 117.85% 90.48%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% -520.90% -371.76% -347.88% -236.93% -337.03% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% -516.00% -369.23% -337.80% -223.58% -318.37% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 493.23% 347.91% 297.07% 175.80% 282.73% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% -27.67% -23.85% -50.81% -61.13% -54.30% -48.64% -101.61% -81.91%
Cash Return on Invested Capital (CROIC)		 0.00% -720.90% -455.56% -443.28% -262.17% -155.08% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% -15.76% -26.59% -50.76% -55.81% -40.64% -31.56% -40.86% -41.83%
Return on Assets (ROA)		 0.00% -13.27% -22.22% -44.41% -47.54% -40.61% -33.23% -48.14% -38.11%
Return on Common Equity (ROCE)		 0.00% -27.67% -23.85% -50.81% -61.13% -54.30% -48.64% -101.61% -81.91%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -13.83% -19.24% -48.60% -67.65% -45.35% -49.83% -186.93% -51.64%
Net Operating Profit after Tax (NOPAT)		 -10 -16 -40 -102 -118 -99 -100 -126 -169
NOPAT Margin		 -830.30% -968.26% -2,862.34% -3,515.98% -6,863.06% -4,237.55% -1,578.39% -7,408.17% -1,669.94%
Net Nonoperating Expense Percent (NNEP)		 0.00% -4.89% -2.53% -10.08% -13.35% -18.66% -13.97% -26.51% -12.45%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -112.84% -39.55%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 112.52%
SG&A Expenses to Revenue		 425.08% 537.45% 1,619.76% 1,356.67% 2,039.18% 1,367.60% 501.56% 2,752.94% 998.87%
R&D to Revenue		 861.06% 945.78% 2,569.30% 3,625.10% 7,865.19% 4,757.04% 1,845.19% 7,684.39% 1,367.94%
Operating Expenses to Revenue		 1,286.14% 1,483.23% 4,189.05% 5,122.83% 9,904.37% 6,153.65% 2,354.84% 10,683.10% 2,373.11%
Earnings before Interest and Taxes (EBIT)		 -14 -23 -54 -142 -167 -142 -141 -177 -242
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -14 -22 -52 -137 -161 -134 -134 -170 -234
Valuation Ratios		 - - - - - - - - -
Price to Book Value (P/BV)		 0.00 1.05 1.16 2.08 1.91 0.87 0.58 10.05 1.46
Price to Tangible Book Value (P/TBV)		 0.00 1.05 1.16 2.08 1.92 0.87 0.58 10.05 1.51
Price to Revenue (P/Rev)		 123.76 88.60 192.34 182.23 234.49 116.60 27.16 659.89 61.80
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 2.18 3.47 7.34 4.43 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 8.09 37.92 109.52 144.64 0.00 0.00 518.35 3.55
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - -
Debt to Equity		 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.00 -0.96 -0.94 -0.88 -0.79 -0.89 -1.13 -1.52 -1.54
Leverage Ratio		 0.00 1.04 1.07 1.14 1.29 1.34 1.46 2.11 2.15
Compound Leverage Factor		 0.00 1.04 1.04 1.12 1.28 1.34 1.54 2.49 1.94
Debt to Total Capital		 0.00% 0.53% 0.12% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.53% 0.12% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% 99.47% 99.88% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 -0.03 -0.01 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 6.08 4.19 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 -0.03 -0.01 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 -0.05 -0.01 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 8.32 5.39 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 -0.05 -0.01 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 15.00 7.21 4.79 -0.14 -0.24 -1.38 -1.54 -1.00
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - -
Current Ratio		 0.00 28.31 11.05 9.98 5.86 12.15 9.18 6.15 10.88
Quick Ratio		 0.00 27.23 10.32 8.43 4.56 10.87 8.25 5.36 9.68
Cash Flow Metrics		 - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -23 -49 -130 -130 -45 -14 -81 -136
Operating Cash Flow to CapEx		 -530.94% -568.85% -345.84% -553.32% -802.11% -1,330.71% -1,035.96% -1,325.20% -934.41%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -41.11 -1.53 -1.80 -14.60
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -106.66 -12.61 -3.23 -22.19
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -114.68 -13.83 -3.47 -24.57
Efficiency Ratios		 - - - - - - - - -
Asset Turnover		 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.00 0.02
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.27 0.11 0.12 0.05 0.07 0.19 0.05 0.24
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 10.99
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 33.21
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -33.21
Capital & Investment Metrics		 - - - - - - - - -
Invested Capital		 0.00 6.29 15 43 56 2.64 -84 -129 -162
Invested Capital Turnover		 0.00 0.54 0.13 0.10 0.03 0.08 -0.16 -0.02 -0.07
Increase / (Decrease) in Invested Capital		 0.00 6.29 9.08 28 13 -53 -87 -45 -33
Enterprise Value (EV)		 0.00 14 53 318 248 -39 -210 880 36
Market Capitalization		 150 150 271 530 402 272 173 1,120 625
Book Value per Share		 $0.00 $10.35 $7.37 $6.35 $4.67 $5.99 $3.29 $0.64 $1.61
Tangible Book Value per Share		 $0.00 $10.35 $7.37 $6.34 $4.67 $5.98 $3.29 $0.64 $1.56
Total Capital		 0.00 143 233 255 210 313 299 111 427
Total Debt		 0.00 0.76 0.29 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.76 0.29 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.00 -136 -217 -211 -154 -311 -383 -240 -589
Capital Expenditures (CapEx)		 1.86 2.88 9.12 18 15 8.86 11 11 22
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 0.38 -5.67 13 9.27 7.73 -3.36 -9.77 11
Debt-free Net Working Capital (DFNWC)		 0.00 137 212 224 163 318 379 231 600
Net Working Capital (NWC)		 0.00 137 212 224 163 318 379 231 600
Net Nonoperating Expense (NNE)		 2.49 3.33 4.48 22 24 43 48 83 52
Net Nonoperating Obligations (NNO)		 0.00 -136 -217 -211 -154 -311 -383 -240 -589
Total Depreciation and Amortization (D&A)		 0.48 1.01 1.71 4.61 5.66 8.46 7.42 6.57 7.72
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 22.39% -402.63% 441.61% 540.23% 331.55% -52.77% -575.38% 106.11%
Debt-free Net Working Capital to Revenue		 0.00% 8,118.67% 15,059.70% 7,712.24% 9,524.78% 13,665.28% 5,965.49% 13,578.62% 5,930.69%
Net Working Capital to Revenue		 0.00% 8,118.67% 15,059.70% 7,712.24% 9,524.78% 13,665.28% 5,965.49% 13,578.62% 5,930.69%
Earnings Adjustments		 - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 ($1.42) ($2.88) ($2.76) ($1.97) ($1.57) ($1.20) ($0.86)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 40.15M 44.98M 52.35M 72.08M 94.99M 173.94M 255.16M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($1.42) ($2.88) ($2.76) ($1.97) ($1.57) ($1.20) ($0.86)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 40.15M 44.98M 52.35M 72.08M 94.99M 173.94M 255.16M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 ($1.42) ($2.88) ($2.76) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 31.56M 43.07M 51.56M 90.91M 173.07M 265.93M 266.13M
Normalized Net Operating Profit after Tax (NOPAT)		 -10 -16 -40 -99 -118 -98 -100 -123 -169
Normalized NOPAT Margin		 -830.30% -968.26% -2,862.34% -3,417.24% -6,863.06% -4,217.24% -1,572.72% -7,236.14% -1,665.54%
Pre Tax Income Margin		 -1,182.10% -1,380.98% -3,698.01% -4,780.19% -9,694.29% -6,096.05% -2,335.96% -12,273.38% -2,165.36%
Debt Service Ratios		 - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -128.67 -15.88 -3.92 -26.06
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -89.35 -11.27 -2.79 -18.18
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -136.69 -17.09 -4.17 -28.43
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -97.37 -12.49 -3.04 -20.56
Payout Ratios		 - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% -5.73% -4.08% -8.06% -6.96% -0.44% -13.31%

Quarterly Metrics And Ratios for Autolus Therapeutics

This table displays calculated financial ratios and metrics derived from Autolus Therapeutics' official financial filings.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Growth Metrics		 - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% -82.86% 0.00% 681.04% 0.00% -100.00% 0.00%
EBITDA Growth		 0.00% 0.00% 0.00% 8.70% 0.00% -5.73% -30.98% -80.34% -30.02%
EBIT Growth		 0.00% 0.00% 0.00% 5.78% 0.00% -5.20% -30.79% -79.11% -29.24%
NOPAT Growth		 0.00% 0.00% 0.00% 1.35% 0.00% 1.00% -32.79% -58.20% -42.41%
Net Income Growth		 0.00% 0.00% 0.00% -7.21% 0.00% -32.35% -27.92% -79.05% 64.23%
EPS Growth		 0.00% 0.00% 0.00% 44.68% 0.00% -4.35% 15.38% -19.23% 80.00%
Operating Cash Flow Growth		 0.00% 0.00% 0.00% 0.00% -70.49% 4.49% -33.91% -90.95% -52.76%
Free Cash Flow Firm Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 24.69% 0.00%
Invested Capital Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -137.87% -25.81%
Revenue Q/Q Growth		 0.00% 0.00% -100.00% 0.00% 0.00% 0.00% -100.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% -16.22% -1.75% -12.01% 0.00% -43.98% -40.09% 19.24%
EBIT Q/Q Growth		 0.00% 0.00% -14.41% -1.38% -12.53% 0.00% -42.24% -38.84% 18.80%
NOPAT Q/Q Growth		 0.00% 0.00% -13.36% 3.32% -24.16% 0.00% -52.05% -15.18% -11.77%
Net Income Q/Q Growth		 0.00% 0.00% -14.42% -0.65% -68.32% 0.00% -10.59% -40.88% 66.37%
EPS Q/Q Growth		 0.00% 0.00% -13.04% 0.00% -73.08% 0.00% 8.33% -40.91% 70.97%
Operating Cash Flow Q/Q Growth		 0.00% -191.22% 10.07% -5.35% 38.21% -63.15% -26.09% -50.23% 50.57%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% -100.00% 0.00% -8.32% -58.13% -134.37%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% -68.82% 0.00% -0.90% -1.37% 10.71%
Profitability Metrics		 - - - - - - - - -
Gross Margin		 100.00% 100.00% 0.00% 100.00% 0.00% 100.00% 0.00% 0.00% -39,165.52%
EBITDA Margin		 -1,993.84% -2,822.52% 0.00% -10,621.43% 0.00% -382.08% 0.00% 0.00% -216,562.07%
Operating Margin		 -1,835.96% -3,030.03% 0.00% -10,567.73% 0.00% -384.07% 0.00% 0.00% -261,600.00%
EBIT Margin		 -1,993.84% -2,969.50% 0.00% -10,961.08% 0.00% -399.98% 0.00% 0.00% -223,165.52%
Profit (Net Income) Margin		 -1,805.28% -3,081.35% 0.00% -11,292.86% 0.00% -522.15% 0.00% 0.00% -95,193.10%
Tax Burden Percent		 87.42% 99.96% 100.09% 99.95% 99.97% 99.98% 100.09% 100.03% 105.60%
Interest Burden Percent		 103.57% 103.80% 103.68% 103.07% 154.15% 130.56% 101.41% 102.97% 40.40%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% 0.00% 0.00% 0.00% -101.61% -38.02% -44.33% -82.20% -81.91%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% -4.66% 0.00% 0.00% -3,900.22%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% -6.08% 0.00% 0.00% -1,663.67%
Return on Common Equity (ROCE)		 0.00% 0.00% 0.00% 0.00% -101.61% -38.02% -44.33% -82.20% -81.91%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% 0.00% 0.00% 0.00% -38.02% -44.33% -56.66% 0.00%
Net Operating Profit after Tax (NOPAT)		 -30 -27 -31 -30 -37 -27 -41 -48 -53
NOPAT Margin		 -1,285.18% -2,121.02% 0.00% -7,397.41% 0.00% -268.85% 0.00% 0.00% -183,120.00%
Net Nonoperating Expense Percent (NNEP)		 0.00% 0.00% 0.00% -12.32% -16.59% -6.73% -4.82% -7.56% 6.15%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - -33.45% - - - -12.43%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 39,265.52%
SG&A Expenses to Revenue		 347.45% 718.58% 0.00% 2,613.55% 0.00% 180.13% 0.00% 0.00% 116,124.14%
R&D to Revenue		 1,588.52% 2,119.81% 0.00% 7,960.10% 0.00% 303.94% 0.00% 0.00% 106,310.34%
Operating Expenses to Revenue		 1,935.96% 3,130.03% 0.00% 10,667.73% 0.00% 484.07% 0.00% 0.00% 223,862.07%
Earnings before Interest and Taxes (EBIT)		 -47 -38 -44 -45 -50 -40 -57 -80 -65
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -47 -36 -42 -43 -48 -39 -56 -78 -63
Valuation Ratios		 - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 2.23 10.05 2.92 1.75 2.03 1.46
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 2.23 10.05 2.92 1.75 2.03 1.51
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 659.89 161.63 88.20 95.72 61.80
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 518.35 89.27 20.85 30.46 3.55
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.00 0.00 0.00 -1.42 -2.16 -1.31 -1.34 -1.39 -1.54
Leverage Ratio		 0.00 0.00 0.00 2.25 2.11 1.55 1.62 1.88 2.15
Compound Leverage Factor		 0.00 0.00 0.00 2.32 3.25 2.02 1.64 1.93 0.87
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% 0.00% 0.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 0.00 0.00 0.00 -0.43 2.62 0.88 0.50 -0.25
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - -
Current Ratio		 0.00 0.00 0.00 8.21 6.15 18.29 18.55 13.69 10.88
Quick Ratio		 0.00 0.00 0.00 6.83 5.36 17.25 17.26 12.52 9.68
Cash Flow Metrics		 - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 0.00 0.00 46 0.00 150 138 58 -20
Operating Cash Flow to CapEx		 0.00% -1,171.15% -869.15% -2,682.78% -1,681.31% -7,601.13% -6,074.08% -800.29% -341.38%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 9.23 0.00 7.80 13.55 5.40 0.00
Operating Cash Flow to Interest Expense		 0.00 -8.65 -7.60 -8.02 -0.82 -2.10 -5.02 -7.18 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 -9.39 -8.47 -8.31 -0.87 -2.13 -5.10 -8.08 0.00
Efficiency Ratios		 - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.02 0.02
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.05 0.31 0.32 0.26 0.24
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 10.99
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 33.21
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -33.21
Capital & Investment Metrics		 - - - - - - - - -
Invested Capital		 0.00 0.00 0.00 -76 -129 -178 -179 -182 -162
Invested Capital Turnover		 0.00 0.00 0.00 0.00 -0.01 -0.12 -0.12 -0.08 -0.07
Increase / (Decrease) in Invested Capital		 0.00 0.00 0.00 -76 0.00 -178 -179 -105 -33
Enterprise Value (EV)		 0.00 0.00 0.00 146 880 937 219 307 36
Market Capitalization		 195 318 412 403 1,120 1,697 926 966 625
Book Value per Share		 $0.00 $0.00 $0.00 $1.04 $0.64 $2.19 $1.98 $1.79 $1.61
Tangible Book Value per Share		 $0.00 $0.00 $0.00 $1.04 $0.64 $2.19 $1.98 $1.79 $1.56
Total Capital		 0.00 0.00 0.00 181 111 582 528 477 427
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.00 0.00 0.00 -257 -240 -760 -707 -659 -589
Capital Expenditures (CapEx)		 0.00 3.62 4.39 1.50 1.48 0.53 0.84 9.59 11
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 0.00 0.00 14 -9.77 0.77 11 7.10 11
Debt-free Net Working Capital (DFNWC)		 0.00 0.00 0.00 271 231 760 718 666 600
Net Working Capital (NWC)		 0.00 0.00 0.00 271 231 760 718 666 600
Net Nonoperating Expense (NNE)		 12 12 14 16 40 26 17 35 -25
Net Nonoperating Obligations (NNO)		 0.00 0.00 0.00 -257 -240 -760 -707 -659 -589
Total Depreciation and Amortization (D&A)		 0.00 1.90 1.51 1.38 1.78 1.81 1.90 1.94 1.92
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% -575.38% 7.33% 102.29% 70.39% 106.11%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 13,578.62% 7,243.15% 6,837.15% 6,596.37% 5,930.69%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 13,578.62% 7,243.15% 6,837.15% 6,596.37% 5,930.69%
Earnings Adjustments		 - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 ($0.26) ($0.45) ($0.24) ($0.22) ($0.31) ($0.09)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 0.00 173.98M 173.94M 222.17M 266.03M 266.08M 255.16M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($0.26) ($0.45) ($0.24) ($0.22) ($0.31) ($0.09)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 0.00 173.98M 173.94M 222.17M 266.03M 266.08M 255.16M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 0.00 173.99M 265.93M 266.04M 266.09M 266.12M 266.13M
Normalized Net Operating Profit after Tax (NOPAT)		 -30 -25 -31 -30 -37 -27 -41 -47 -53
Normalized NOPAT Margin		 -1,285.18% -1,916.87% 0.00% -7,331.55% 0.00% -268.85% 0.00% 0.00% -183,120.00%
Pre Tax Income Margin		 -2,064.96% -3,082.43% 0.00% -11,298.03% 0.00% -522.23% 0.00% 0.00% -90,148.28%
Debt Service Ratios		 - - - - - - - - -
EBIT to Interest Expense		 -25.53 -7.82 -8.74 -8.88 -1.66 -2.09 -5.64 -7.46 0.00
NOPAT to Interest Expense		 -16.46 -5.59 -6.19 -5.99 -1.24 -1.41 -4.05 -4.45 0.00
EBIT Less CapEx to Interest Expense		 0.00 -8.56 -9.62 -9.17 -1.71 -2.12 -5.73 -8.36 0.00
NOPAT Less CapEx to Interest Expense		 0.00 -6.33 -7.06 -6.29 -1.29 -1.44 -4.14 -5.34 0.00
Payout Ratios		 - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% -0.44% -12.54% -12.55% -10.86% -13.31%

Financials Breakdown Chart

Key Financial Trends

Autolus Therapeutics plc (NASDAQ: AUTL) has continued to show characteristics typical of a clinical-stage biotech company with no consistent product revenue yet, and heavy ongoing investment in R&D and SG&A expenses.

Key positive points from recent financials:

  • Q4 2024 reported $29,000 in operating revenue – a sign of initial commercial activity though still very limited.
  • Substantial cash reserves: as of Q3 2024, cash and equivalents stood around $657 million, providing a significant runway.
  • Quarterly net cash used in operating activities has narrowed from Q3 2024 (-$76.7M) to Q4 2024 (-$36.7M), showing some improvement in cash burn.
  • Investment in property, plant, and equipment continues steadily, indicating capacity building for future operations.

Neutral factors to watch:

  • The company has no consistent revenue streams yet outside minimal operating revenue sporadically reported.
  • Weighted average diluted shares outstanding has increased moderately over the years, impacting EPS calculations.
  • Autolus has minimal current liabilities relative to assets, which suggests a manageable short-term debt position.

Negative points to consider:

  • Consistent quarterly net losses continuing into Q4 2024 (-$27.6M) with annualized losses running into the hundreds of millions, e.g., Q3 2024 net loss was -$82.1M.
  • High R&D expenses persist in Q4 2024 ($30.8M), reflecting heavy ongoing clinical development costs without offsetting revenue.
  • Selling, general & administrative expenses remain substantial at $33.7M in Q4 2024, indicative of scaling operational and commercial support costs before meaningful sales.
  • Interest expense surged in Q4 2024 to $30.8M, significantly higher than prior quarters, negatively impacting pretax income.
  • Net cash flows from investing activities are heavily negative, especially in Q4 2024 (-$383.6M), likely due to investments or acquisitions, stressing cash reserves.
  • Exchange rate effects negatively impacted cash in Q4 2024 by approximately $38.2M, reflecting currency risk exposure.

Overall Trend Analysis:

Autolus has been consistently operating at a significant loss while investing heavily in R&D and scaling commercial infrastructure. Despite minimal revenue starting to appear, it remains negligible against expenses. The company has been successfully capitalizing capital (note $549.9M share issuance in Q1 2024) to maintain healthy cash reserves, which are gradually declining due to high cash burn. The interest expense increase in recent quarters is notable and may warrant closer attention to overall debt or financing costs.

For retail investors, the outlook depends heavily on Autolus advancing its clinical pipeline towards potential commercial success. The financials confirm a classic biotech profile: high investment and losses balanced by substantial cash reserves, but no predictable profits yet.

10/26/25 01:09 AM ETAI Generated. May Contain Errors.

Frequently Asked Questions About Autolus Therapeutics' Financials

When does Autolus Therapeutics' financial year end?

According to the most recent income statement we have on file, Autolus Therapeutics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Autolus Therapeutics' net income changed over the last 8 years?

Autolus Therapeutics' net income appears to be on an upward trend, with a most recent value of -$220.66 million in 2024, rising from -$12.55 million in 2016. The previous period was -$208.38 million in 2023. See where experts think Autolus Therapeutics is headed by visiting Autolus Therapeutics' forecast page.

What is Autolus Therapeutics' operating income?
Autolus Therapeutics' total operating income in 2024 was -$241.43 million, based on the following breakdown:
  • Total Gross Profit: -$1.27 million
  • Total Operating Expenses: $240.16 million
How has Autolus Therapeutics' revenue changed over the last 8 years?

Over the last 8 years, Autolus Therapeutics' total revenue changed from $1.21 million in 2016 to $10.12 million in 2024, a change of 735.0%.

How much debt does Autolus Therapeutics have?

Autolus Therapeutics' total liabilities were at $355.40 million at the end of 2024, a 34.7% increase from 2023, and a 5,763.7% increase since 2017.

How much cash does Autolus Therapeutics have?

In the past 7 years, Autolus Therapeutics' cash and equivalents has ranged from $137.07 million in 2017 to $382.44 million in 2022, and is currently $227.38 million as of their latest financial filing in 2024.

How has Autolus Therapeutics' book value per share changed over the last 8 years?

Over the last 8 years, Autolus Therapeutics' book value per share changed from 0.00 in 2016 to 1.61 in 2024, a change of 160.6%.


Related Companies

This page (NASDAQ:AUTL) was last updated on 10/26/2025 by MarketBeat.com Staff
From Our Partners
U.S. Government Sparking Crypto Rally
Missed Bitcoin when it was $100? You’re not alone. Crypto runs in cycles—and the next one is already underw...
Crypto 101 Media | Sponsoredtc pixel
A Worldwide Gold Lockdown Is Now Underway
Central banks around the world are hoarding gold at one of the fastest rates in history — and former Goldman S...
Stansberry Research | Sponsoredtc pixel
Trump’s new nightmare begins
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...
Porter & Company | Sponsoredtc pixel
Buy the dip? Here’s my #1 gold stock
“The most obvious opportunity in gold stocks I’ve seen in my career” While everyone is distracted by gold’s...
Golden Portfolio | Sponsoredtc pixel
The strategy that wins no matter where the market goes
Joel and Adam have built a crypto trading system with a 93% win rate — even through volatile, sideways markets...
Crypto Swap Profits | Sponsoredtc pixel
Elon Musk is on the line
Elon Musk says November 6 could "affect the future of the world" Get ready for the biggest pivot in corpora...
Altimetry | Sponsoredtc pixel
If You Keep Cash In A U.S. Bank Account… Read This NOW
The Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...
Banyan Hill Publishing | Sponsoredtc pixel
The End of Elon Musk…?
While headlines point to collapsing sales and fading tax credits, tech analyst Jeff Brown says Tesla is on the...
Brownstone Research | Sponsoredtc pixel